XORTX Announces Closing of US$5 Million Public Offering
XORTX closes deep-discount offering with half the proceeds going to investor relations, signaling potential desperation and further dilution ahead.
The most recent news (May 19, 2026) confirms the closing of XORTX’s previously announced US$5 million public offering. A total of 2,659,574 common shares or pre-funded warrants were issued at US$1.88 each. Notably, US$2.5 million of the gross proceeds – fully 50% – will be paid to IR Agency LLC for marketing, media distribution, and digital community building. The offering was placed by E.F. Hutton & Co., which received a 4% cash commission.
This closing is an expected, procedural event following the pricing and announcement earlier in the week. It adds no new favorable information. The offering itself was severely dilutive: priced at US$1.88 while the stock was trading around $3.50‑$3.77 only days before, reflecting a desperate need for capital. The allocation of half the proceeds to IR activities is exceptionally high for a development‑stage biotech and raises serious concerns about management’s priorities and the sustainability of the business. While the closing is routine, the underlying capital raise is a material negative that further erodes shareholder value and signals ongoing cash burn with no immediate clinical catalysts.
XORTX Therapeutics is a clinical‑stage biotech focused on progressive kidney disease. Its pipeline originated with therapies for gout and autosomal dominant polycystic kidney disease (ADPKD). The recent acquisition (closed April 2026) of Vectus Biosystems’ VB4‑P5 adds a novel pre‑IND anti‑fibrotic small molecule for rare and prevalent kidney diseases. However, the flagship asset is still early‑stage, with no visible near‑term clinical data.